A randomized, double-blind, placebo-controlled study in 93 children diagnosed with functional abdominal pain showed that L. reuteri Protectis reduced both frequency and severity of pain compared to placebo. “According to the results, physicians facing the common and challenging problem of functional abdominal pain in children might suggest the use of L. reuteri Protectis, as an accessible way to relieve pain intensity and reduce its frequency“, says Professor Zvi Weizman from the Paediatric Gastroenterology and Nutrition Unit, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva, Israel. After four weeks of intervention the number of pain episodes were almost halved among the children supplemented with one chewable tablet per day of L. reuteri Protectis compared to the placebo group. The severity of pain was also significantly reduced in the probiotic group compared to placebo and this effect persisted during the follow-up period. “Stomach pain is common among children and often affects the child’s daily life through for example anxiety and school absenteeism. It is therefore very gratifying that this study, which confirms earlier results with L. reuteri Protectis, shows that BioGaia ProTectis could offer these children an effective, safe and easy option”, says Axel Sjöblad, Managing Director, BioGaia. The study was published online in the Journal of Pediatrics (http://www.ncbi.nlm.nih.gov/pubmed/27156182) 4 May 2016. Study facts (http://www.biogaia.com/sites/biogaia.com/files/Study_facts_Weizman_2016.p d f) and an interview (http://www.biogaia.com/interview-professor-zvi -weizman) with the principal investigator, Professor Zvi Weizman are found through the attached links. Latest press releases from BioGaia 2016-05-11 Annual General Meeting of BioGaia 2016-05-10 BioGaia AB – Interim management statement 1 January - 31 March 2016 2016-05-02 Yet another meta-analysis confirms the effectiveness of BioGaia’s probiotic in infantile colic BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 17 May 2016, 01:00 pm CET. For additional information please contact Axel Sjöblad, Managing Director, BioGaia: +46 8 555 293 00 BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri which has probiotic, health -enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of NASDAQ Stockholm main market. www.biogaia.com